XASXRHY
Market cap15mUSD
Jan 09, Last price
0.09AUD
1D
0.00%
1Q
-13.13%
IPO
-72.70%
Name
Rhythm Biosciences Ltd
Chart & Performance
P/E
—
P/S
14.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.12%
Rev. gr., 5y
10.46%
Revenues
2m
-45.41%
Net income
-7m
L-16.56%
CFO
-6m
L-11.79%
Earnings
Feb 26, 2025
Profile
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑08 | 2017‑06 | |
| Income | |||||||||
Revenues | 1,690 -45.41% | 3,096 27.54% | 2,427 118.98% | ||||||
Cost of revenue | 6,727 | 11,343 | 11,156 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,037) | (8,247) | (8,728) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,690) | (228) | (2,477) | ||||||
Tax Rate | |||||||||
NOPAT | (3,347) | (8,019) | (6,251) | ||||||
Net income | (6,857) -16.56% | (8,218) 30.10% | (6,316) -18.20% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,897 | 3,716 | 11,853 | ||||||
BB yield | -20.47% | -4.09% | -4.81% | ||||||
| Debt | |||||||||
Debt current | 78 | 85 | 86 | ||||||
Long-term debt | 249 | 85 | 255 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 4 | 55 | 49 | ||||||
Net debt | (427) | (4,000) | (7,255) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (6,137) | (6,958) | (6,215) | ||||||
CAPEX | (82) | (99) | (27) | ||||||
Cash from investing activities | (82) | (99) | (27) | ||||||
Cash from financing activities | 2,805 | 3,630 | 11,845 | ||||||
FCF | (2,169) | (9,233) | (6,378) | ||||||
| Balance | |||||||||
Cash | 754 | 4,169 | 7,595 | ||||||
Long term investments | |||||||||
Excess cash | 670 | 4,014 | 7,474 | ||||||
Stockholders' equity | 867 | 5,874 | 7,372 | ||||||
Invested Capital | 365 | 2,000 | 219 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 228,297 | 221,542 | 214,445 | ||||||
Price | 0.06 -84.88% | 0.41 -64.35% | 1.15 29.94% | ||||||
Market cap | 14,154 -84.42% | 90,832 -63.17% | 246,612 46.70% | ||||||
EV | 13,728 | 86,832 | 239,357 | ||||||
EBITDA | (4,838) | (8,058) | (8,627) | ||||||
EV/EBITDA | |||||||||
Interest | 3 | 25 | |||||||
Interest/NOPBT | |||||||||